Digbi Health is positioning itself at the center of a structural shift in obesity care—where rising GLP-1 demand is forcing employers to rethink traditional pharmacy benefit models.
With the launch of Digbi RxFund™ and the expansion of its GLP-1 Compass platform, the company is introducing a hybrid financial + clinical model that moves away from opaque, all-or-nothing PBM coverage toward flexible, employer-controlled funding pathways.
But the real differentiation lies beyond financing. Digbi is attempting to manage the entire GLP-1 lifecycle—from prevention and patient selection to tolerability and long-term dependency—using a combination of genetics, gut microbiome insights, and metabolic data.
This reflects a broader shift in healthcare: GLP-1s are no longer just a drug category—they are becoming a cost, behavior, and biology management problem.
By tying subsidies to patient engagement and layering precision biology into treatment decisions, Digbi is betting that the future of obesity care won’t be driven by access alone—but by who should be on these drugs, how they respond, and how long they stay on them.